Patients

Patient commitment

At Geron, we share a deep-rooted commitment to bringing the potential power of telomerase inhibition to patients. Our science, expertise and readiness to bring imetelstat to market could transform the treatment landscape of blood cancers, which drives our single-minded urgency to deliver innovative therapies to patients.


Clinical trials

To learn about our clinical trials, click here.

To see clinical trials that are currently underway and to find out if a study is enrolling patients with your condition and in your area, please visit www.clinicaltrials.gov. If you have any questions regarding ongoing clinical trials of imetelstat, please contact info@geron.com.

To learn more about clinical trials, please visit Cancer.gov.

Our commitment comes from our understanding of the significant impact we can make for patients with certain hematologic malignancies.


About Myelodysplastic Syndromes (MDS)

Patients with lower risk MDS require frequent blood transfusions to manage anemia and thrombocytopenia (low platelet counts) complications. Many patients become transfusion dependent, which in turn requires frequent visits to a hospital or specialty clinic that negatively impact quality of life. Patients who are transfusion dependent have been shown to have poorer prognoses.

Today’s approved therapies for patients who are anemic due to lower risk MDS lack sufficient durable transfusion independence and broad applicability across patient subgroups. There is an unmet need for a treatment advance that will provide depth, breadth and durability of transfusion independence and safety for lower risk MDS patients, especially those who are heavily transfusion dependent.


About Myelofibrosis (MF)

Patients with MF are typically treated with janus associated kinase inhibitors (JAKis). Unfortunately, the majority of patients become unresponsive to JAKis within five years, resulting in very poor overall survival prognosis. There is an urgent need for a drug that can extend survival and be taken by patients who become relapsed/refractory to JAKis.


About Acute Myeloid Leukemia (AML)

The current treatment approach for AML consists of chemotherapy (anthracycline plus cytarabine), an approach that has been largely unchanged for more than 40 years, or chemotherapy plus a targeted therapy against specific mutations. Despite initial response to these treatments, the majority of AML patients will suffer a relapse, at which point the condition is incurable with standard therapy. New treatments that can improve outcomes after chemotherapy are critical to extending and enhancing the lives of patients with AML.


Expanded access policy

Currently, Geron does not offer an expanded access program, and does not accept expanded access requests. We believe that access to imetelstat should be limited to controlled clinical trials until such time as its safety, tolerability and effectiveness for a particular indication has been determined and confirmed by regulatory authorities. Patient access to imetelstat outside of a controlled clinical trial may interfere with the conduct of our ongoing and future clinical trials and may also disrupt the progress of our development program, which would, in turn, delay access to many patients in need.

Accordingly, while clinical trials are ongoing, we believe participation in our clinical trials is the only safe and appropriate way to access imetelstat.

If you have questions about Geron’s expanded access policy, please contact Geron at info@geron.com. Please expect a response within five business days.

In line with the 21st Century Cures Act, Geron may revise this policy at any time.